QQ客服 官方微博 反馈留言

浏览/检索结果: 共7条，第1-7条 帮助 限定条件 发表日期：2017     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 期号: 1 作者:  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua;  Wang, Zhehai 收藏  |  浏览/下载：14/0  |  提交时间：2019/12/04 NSCLC  Anlotinib  multi-targeted tyrosine kinase inhibitor   Downregulation of P38 phosphorylation correlates with low-grade differentiation and proliferation of lung squamous cell carcinoma 期刊论文 AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 卷号: 9, 页码: 1922-1933 作者:  Nan, Yandong;  Chang, Ruijing;  Jiang, Hua;  Yang, Shuanying;  Jin, Faguang 收藏  |  浏览/下载：4/0  |  提交时间：2019/11/26 P-P38  Lung squamous carcinoma  LSCC  proliferation  P38MAPK   A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 页码: S886-S887 作者:  Han, Baohui;  Li, Kai;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li 收藏  |  浏览/下载：9/0  |  提交时间：2019/11/26 NSCLC  multi-targeted tyrosine kinase inhibitor  Anlotinib   Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study 期刊论文 LANCET ONCOLOGY, 2017, 卷号: 18, 页码: S3-S3 作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhao, Yizhuo;  Zhang, Li 收藏  |  浏览/下载：10/0  |  提交时间：2019/11/26 Early Candidate Biomarkers of Non-Small Cell Lung Cancer Are Screened and Identified in Premalignant Lung Lesions 期刊论文 TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2017, 卷号: 16, 页码: 66-74 作者:  Nan, Yandong;  Du, Jie;  Ma, Lijie;  Jiang, Hua;  Jin, Faguang 收藏  |  浏览/下载：2/0  |  提交时间：2019/11/26 proteomics  C-Src  early diagnosis  FAK  biomarkers  NSCLC   Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study 期刊论文 2017, 卷号: 18, 页码: S3-S3 作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhao, Yizhuo;  Zhang, Li 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) 期刊论文 2017, 卷号: 12, 期号: 1, 页码: S886-S887 作者:  Han, Baohui;  Li, Kai;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li 收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03 NSCLC  Anlotinib  multi-targeted tyrosine kinase inhibitor